Wall Street brokerages forecast that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will report ($0.76) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for Lexicon Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.80) and the highest is ($0.71). Lexicon Pharmaceuticals reported earnings of ($0.16) per share in the same quarter last year, which indicates a negative year over year growth rate of 375%. The firm is expected to report its next earnings results on Wednesday, March 11th.
According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of $0.83 per share for the current fiscal year, with EPS estimates ranging from $0.78 to $0.87. For the next financial year, analysts expect that the company will post earnings of ($1.96) per share, with EPS estimates ranging from ($2.40) to ($1.55). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.31 by $0.80. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The business had revenue of $294.45 million during the quarter, compared to analyst estimates of $12.00 million. During the same quarter in the previous year, the firm earned ($0.26) EPS. Lexicon Pharmaceuticals’s revenue was up 4124.5% on a year-over-year basis.
A number of brokerages have weighed in on LXRX. Citigroup lowered Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $3.00 to $4.00 in a research report on Friday, November 8th. Gabelli raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research report on Wednesday, September 11th. ValuEngine raised Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Wedbush reissued a “buy” rating and issued a $17.00 target price on shares of Lexicon Pharmaceuticals in a research report on Monday. Finally, Zacks Investment Research lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 16th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company’s stock. Lexicon Pharmaceuticals has an average rating of “Hold” and an average target price of $6.45.
NASDAQ:LXRX traded up $0.47 during mid-day trading on Wednesday, reaching $3.77. The company’s stock had a trading volume of 1,995,599 shares, compared to its average volume of 1,297,426. Lexicon Pharmaceuticals has a 12-month low of $1.13 and a 12-month high of $8.39. The firm’s fifty day moving average price is $3.63 and its two-hundred day moving average price is $3.88. The company has a current ratio of 8.11, a quick ratio of 8.01 and a debt-to-equity ratio of 1.42. The stock has a market cap of $400.65 million, a P/E ratio of -3.31 and a beta of 1.00.
In other news, Director Christopher J. Sobecki purchased 25,000 shares of the business’s stock in a transaction on Monday, September 16th. The stock was acquired at an average cost of $2.55 per share, for a total transaction of $63,750.00. Following the purchase, the director now directly owns 112,493 shares in the company, valued at approximately $286,857.15. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Christopher J. Sobecki purchased 99,249 shares of the business’s stock in a transaction on Friday, September 13th. The shares were purchased at an average price of $2.41 per share, with a total value of $239,190.09. Following the completion of the purchase, the director now owns 13,645 shares in the company, valued at $32,884.45. The disclosure for this purchase can be found here. In the last three months, insiders acquired 178,749 shares of company stock valued at $474,560. 6.40% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in LXRX. Point72 Asset Management L.P. bought a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at about $1,590,000. Vanguard Group Inc. grew its stake in shares of Lexicon Pharmaceuticals by 8.1% during the 2nd quarter. Vanguard Group Inc. now owns 4,240,111 shares of the biopharmaceutical company’s stock valued at $26,670,000 after purchasing an additional 319,382 shares during the period. Wedbush Securities Inc. grew its stake in shares of Lexicon Pharmaceuticals by 105.1% during the 3rd quarter. Wedbush Securities Inc. now owns 398,684 shares of the biopharmaceutical company’s stock valued at $1,200,000 after purchasing an additional 204,345 shares during the period. First Manhattan Co. grew its stake in shares of Lexicon Pharmaceuticals by 7.3% during the 2nd quarter. First Manhattan Co. now owns 2,949,979 shares of the biopharmaceutical company’s stock valued at $18,555,000 after purchasing an additional 201,393 shares during the period. Finally, Virtus ETF Advisers LLC bought a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at about $901,000. Institutional investors and hedge funds own 96.27% of the company’s stock.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Further Reading: What impact do institutional investors have on markets?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.